Cladribine for MS: Fewer Relapses, Key Questions Remain

Credibility

Interest

Key Takeaway

Cladribine is an oral MS treatment that likely lowers relapses but may not clearly slow disability, with uncertain long-term benefits and safety that need more study.

What They Found

Researchers combined results from 15 studies to see how cladribine works for people with MS. Cladribine probably cuts the chance of having new relapses (attacks) compared with placebo, which means fewer flare-ups for many people. It may also lower some MRI signs of inflammation in the brain, but the MRI results vary a lot between studies. Cladribine did not show a clear effect on slowing disability over about two years — people were about as likely to get worse as with placebo. Short-term and longer-term safety results were uncertain: serious side effects were similar to placebo in most studies, but overall side-effect data had low certainty so we can’t be sure how safe it is long-term.

Who Should Care and Why

People with relapsing MS who want an oral treatment that is given in short courses (reducing how often you need daily pills or frequent clinic visits) should care because cladribine may lower relapses, which can protect against symptoms that interrupt daily life. Caregivers may notice fewer relapses for someone on cladribine, which can mean fewer emergency visits or disruptions to routines. Healthcare providers should care because cladribine’s convenience (short courses over two years) can reduce treatment burden, but they need to watch patients carefully because long-term safety and effects on disability are unclear. People considering switching treatments or choosing a first treatment can weigh the likely benefit on relapses against uncertain effects on disability and the need for more evidence on long-term safety. If you value fewer clinic visits and taking medicine in short courses (like a short-course vaccine compared to daily pills), cladribine’s schedule may be especially appealing.

Important Considerations

Most evidence is low or very low certainty, meaning the results could change with better studies, so treat conclusions as tentative. Many important outcomes—like quality of life and thinking problems—were not reported, so we don’t know how cladribine affects daily function or memory. Long-term safety and differences versus other MS drugs remain uncertain, so close follow-up with your care team is important if you choose this treatment.

Categories:

Treatment Updates Clinical Trials Living with MS

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The Cochrane database of systematic reviews often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News